ONKURE THERAPEUTICS INC-A
OKURNASDAQ🏆 #3935 by market capUS Equity
$2.52▼ $0.11 (−4.37%)
Latest quoteTrack OKUR
Get earnings, price moves & breaking news on Telegram
24h▼ 4.4%
7d▼ 2.5%
14d▲ 19.2%
30d▼ 3.1%
ytd▼ 12.1%
1y▼ 21.2%
🏦Market Cap
$102M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $2.49 – $2.67
- 52-Week Range
- $2.01 – $5.38
- Volume (shares)
- 4,461
- Avg Volume (shares)
- —
- Shares Outstanding
- 40.5M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-3.50
- Dividend Yield
- —
- Dilution (1yr)
- +1.3%
ONKURE THERAPEUTICS INC-A
OKURFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$63M▲ +15.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$52M▲ +1.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
13.5M▲ +1.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$59M▼ −$51M YoY
StockOtter · stockotter.spaceAbout ONKURE THERAPEUTICS INC-A
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.
Latest News & Updates
News unavailable.